LPL Financial’s Third Harmonic Bio THRD Stock Holding History

LPL Financial’s Portfolio THRD Stock Details THRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,000	Closed	-$41.2K	–	4683
2023 Q1	$41.2K	Hold	10,000	–	–	﹤0.01%	4335
2022 Q4	$43K	Buy	+10,000	New	+$167K	﹤0.01%	4285

Other funds holding THRD

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPL Financial's THRD Position: Q2 2023 in Review

LPL Financial sold out of Third Harmonic Bio (THRD) in Q2 2023, closing a stake of 10,000 shares — an estimated $41.2K sold.

LPL Financial first reported a position in THRD in Q4 2022 and held it in 2 quarters. The position peaked at $43K in Q4 2022. 48 funds tracked by Wall St. Rank hold THRD as of Q2 2023.

LPL Financial reported no remaining Third Harmonic Bio position as of Q2 2023 after selling out during the quarter.
LPL Financial sold 10,000 Third Harmonic Bio shares in Q2 2023, an estimated $41.2K.
LPL Financial first reported a position in Third Harmonic Bio in Q4 2022 and held it in 2 quarters.
LPL Financial's Third Harmonic Bio position peaked at $43K in Q4 2022.
48 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q2 2023.

Based on LPL Financial's 13F filing for Q2 2023, filed 31 Jul 2023.